Semaglutide

Overview

Evidence tier: 5 — editorial framing of the peptide-page entity context.

Semaglutide is the most commercially significant peptide therapy of the modern era. Approved by the FDA in 2017 as Ozempic for type 2 diabetes, again in 2021 as Wegovy for chronic weight management, again in 2019 as Rybelsus for oral diabetes treatment, and most recently in 2023–2025 for cardiovascular risk reduction, chronic kidney disease, and MASH (fatty liver disease). It is the molecule responsible for the cultural and commercial earthquake around GLP-1 medications — Novo Nordisk briefly became Europe's most valuable company on the strength of its semaglutide portfolio.

Mechanistically it is a long-acting GLP-1 receptor agonist: a 31-amino-acid synthetic peptide engineered with two key modifications from the natural human GLP-1 hormone. First, an alpha-aminoisobutyric acid substitution at position 8 protects against degradation by the dipeptidyl peptidase-4 enzyme that normally inactivates GLP-1 within minutes. Second, a fatty acid side chain on a lysine residue allows reversible binding to albumin in plasma, dramatically extending half-life. Together these modifications turn a peptide hormone with a 2-minute half-life into a drug with a 7-day half-life suitable for once-weekly dosing.

How it works

Evidence tier: 2 — mechanism documented in published pharmacology literature.

GLP-1 is an incretin hormone naturally released by L-cells in the small intestine after eating. Its physiological role is to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and signal satiety to the brain. Semaglutide mimics this signal but at a sustained, supraphysiologic level.

The clinical effects unpack into several distinct mechanisms:

• Pancreatic insulin enhancement. Semaglutide stimulates beta cells to release insulin in response to glucose — but only when blood glucose is elevated. This glucose-dependence is why it rarely causes hypoglycemia on its own, in contrast to insulin or sulfonylureas.
• Glucagon suppression. Reduces hepatic glucose output during the postprandial period.
• Slowed gastric emptying. Food remains in the stomach longer, contributing to increased satiety duration. This effect is also responsible for most GI side effects.
• Central appetite suppression. GLP-1 receptors in the hypothalamus and brainstem (area postrema, nucleus tractus solitarius) modulate hunger signaling. The 15–20% weight loss seen with semaglutide reflects sustained reduction in caloric intake driven by genuine appetite suppression rather than willpower.
• Cardiovascular and renal benefits. Independent of weight loss, semaglutide produces measurable reductions in major adverse cardiac events (20% in SELECT) and slows progression of diabetic kidney disease (FLOW trial).

What the evidence actually shows

Evidence tier: 2 — references summarized in the body; see Trial readouts section below for primary-source detail.

Semaglutide has the strongest evidence base of any peptide therapy currently in use:

• STEP 1 (2021). Weight management RCT, n=1,961 adults with obesity. 14.9% mean weight loss over 68 weeks vs 2.4% placebo. Tier 1.
• STEP 2 (2021). Adults with overweight/obesity AND type 2 diabetes. 9.6% weight loss vs 3.4% placebo. Tier 1.
• STEP 3 / 4 / 5. Various populations and intensifications; consistent 12–18% weight loss range. Tier 1.
• SELECT (2023). Cardiovascular outcomes trial, n=17,604 with cardiovascular disease but without diabetes. 20% reduction in major adverse cardiac events. Tier 1.
• FLOW (2024). Renal outcomes trial in T2D + CKD. Significant reduction in kidney disease progression. Tier 1.
• SURPASS comparisons. Tirzepatide outperformed semaglutide in head-to-head trials; semaglutide remains the GLP-1 baseline.

By any reasonable standard this is a well-validated drug across multiple indications.

Reported benefits

Evidence tier: 5 — editorial framing of the peptide-page entity context.

In published trials and clinical practice:

• 14–20% body weight reduction over 12–18 months at full dose.
• Substantial improvement in HbA1c (1.5–2.0% reduction in T2D).
• 20% reduction in major adverse cardiac events (SELECT, in patients with established cardiovascular disease).
• Slowed progression of diabetic kidney disease.
• Reductions in liver fat and improvement in MASH histology.
• Emerging evidence in obstructive sleep apnea (where tirzepatide has formal approval), Alzheimer's disease, and substance-use disorders. Trials ongoing.

Risks and reported side effects

Evidence tier: 3 — clinical case-series + animal-model adverse-event data; magnitude varies by molecule.

Most common (>10% of patients):

• Nausea, vomiting, diarrhea, constipation — concentrated during titration. About 5–10% of patients discontinue due to GI intolerance.
• Reduced appetite (the desired effect, but uncomfortable for some).

Less common but clinically important:

• Acute pancreatitis — rare but real. Discontinue if suspected.
• Acute kidney injury, usually in the context of severe vomiting or diarrhea causing dehydration.
• Gallbladder disease — modest increased risk.
• Diabetic retinopathy progression in some T2D patients with pre-existing retinopathy.
• Possible association with thyroid C-cell tumors based on rodent data (black-box warning); not clearly demonstrated in human cohorts but contraindicated in personal/family history of medullary thyroid carcinoma or MEN 2.

The discontinuation reality:

• Stopping semaglutide typically results in significant weight regain — published data shows roughly two-thirds of weight loss is regained within a year of discontinuation. This is not a "willpower failure"; it is the predictable physiology of an appetite-suppressing drug being withdrawn.

Practical considerations

Evidence tier: 5 — community-evolved dose-range guidance; not RCT-derived.

• Branded vs compounded. FDA-approved branded semaglutide (Wegovy, Ozempic, Rybelsus) costs $900–1,350/month without insurance. Compounded semaglutide from licensed pharmacies — operating in a legally contested zone — typically costs $200–500/month. The legal landscape is actively shifting; verify status.
• Dosing. Standard weekly titration: 0.25 mg → 0.5 → 1.0 → 1.7 → 2.4 mg. Most patients reach maximal benefit at 1.7–2.4 mg. Some clinicians use lower long-term maintenance doses.
• Injection technique. Subcutaneous, abdomen or thigh. Pen devices make this trivial.
• GI tolerability. Slow titration and dietary changes (smaller portions, lower fat) substantially reduce nausea.
• Discontinuation planning. If stopping, expect weight regain. Some clinicians transition to lower maintenance doses rather than full discontinuation.

Where to go from here

Evidence tier: 5 — editorial framing of the peptide-page entity context.

For the head-to-head comparison with tirzepatide, see the comparison page (forthcoming). For oral semaglutide options including Rybelsus, see the supporting article on oral GLP-1s. For the broader Weight Loss pillar including AOD-9604 and other secondary peptides, see the goal-based hub.

For an endocrinologist or obesity-medicine clinician interested in becoming a Medical Reviewer for our Weight Loss cluster content, see the Medical Review Process page.

Related on Peptide Story

• Weight Loss pillar — GLP-1 receptor agonists
• Semaglutide vs Tirzepatide — head-to-head
• Tapering off GLP-1s without rebound

References

• Wilding J.P.H. et al. 2021. STEP-1: Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med.
• Lincoff A.M. et al. 2023. SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med.